These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29905380)

  • 21. Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review.
    Gu H; Lee WI; Jeon Y; Kang SY; Kim MH; Park TS
    Clin Lab; 2017 Feb; 63(2):373-378. PubMed ID: 28182355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Uchida T; Hagihara M; Hua J; Inoue M
    Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
    Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
    Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminated varicella-zoster virus infection following azacitidine in a patient with myelodysplastic syndrome.
    Zhou G; Houldin AD
    Clin J Oncol Nurs; 2009 Jun; 13(3):280-4. PubMed ID: 19502185
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.
    McNee G; Eales KL; Wei W; Williams DS; Barkhuizen A; Bartlett DB; Essex S; Anandram S; Filer A; Moss PA; Pratt G; Basu S; Davies CC; Tennant DA
    Leukemia; 2017 Feb; 31(2):373-381. PubMed ID: 27400413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    Crowley MP; Kevane B; O'Shea SI; Quinn S; Egan K; Gilligan OM; Ní Áinle F
    Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and outcomes in biclonal gammopathies.
    Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):827-32. PubMed ID: 20332755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sclerosing mesenteritis as a presentation of myelodysplastic syndrome (MDS) with improvement following treatment targeted at MDS.
    Elnair R; Sethi P; Hassouna T; Galal A
    Ann Hematol; 2018 Mar; 97(3):547-549. PubMed ID: 29134269
    [No Abstract]   [Full Text] [Related]  

  • 34. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
    Santini V
    Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azacitidine in lower-risk myelodysplastic syndromes.
    Santini V
    Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical and basic aspects of monoclonal gammopathy of undetermined significance (MGUS)].
    Takamatsu Y
    Rinsho Ketsueki; 2013 Aug; 54(8):702-4. PubMed ID: 24005426
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.